Meanwhile, QPCR results revealed that compared with MASLD model mice, the expression of lipogenesis-related genes ACC, FAS, SREBP1, and SCD1 in the livers of mice treated with LGG was significantly reduced, suggesting that in the early stages of the disease, LGG can alleviate MASLD by regulating the composition of the intestinal microbiota, especially the abundance of Bacteroidetes, thereby promoting the production and accumulation of SCFAs (Tian et al., 2024). This evidence concerns the gene FAS and metabolic dysfunction-associated steatotic liver disease.